DEL_Biogaia AB ((DEL_0GTN)), BioGaia AB Class B ((GB:0GTN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioGaia AB is currently conducting a clinical study titled ‘A Double-blind, Randomised, Placebo-controlled, Parallel-group Study Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic.’ The study aims to assess the effectiveness of the probiotic L. Reuteri in reducing crying and fussing time in colicky infants, a condition that can cause significant distress for both infants and parents.
The intervention being tested is a dietary supplement containing L. Reuteri, administered as drops once daily for 21 days. The study includes a placebo group receiving identical drops without the probiotic, allowing for a clear comparison of outcomes.
This interventional study follows a randomized, parallel-group design with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the group assignments. The primary purpose is treatment-focused, aiming to provide relief for infants suffering from colic.
The study began on June 9, 2025, with the latest update submitted on June 23, 2025. These dates are crucial as they mark the commencement of participant recruitment and the most recent information available, respectively.
The ongoing study could potentially impact BioGaia AB’s market performance positively if results demonstrate a significant benefit of L. Reuteri in managing colic. This could enhance investor confidence and position BioGaia favorably against competitors in the probiotic market.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.